ADCT
Price
$1.59
Change
+$0.09 (+6.00%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
191.5M
18 days until earnings call
Intraday BUY SELL Signals
SEPN
Price
$40.84
Change
+$0.09 (+0.22%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
1.9B
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADCT vs SEPN

ADCT vs SEPN Comparison Chart in %
View a ticker or compare two or three
VS
ADCT vs. SEPN commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADCT is a Hold and SEPN is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ADCT with price predictions
Oct 21, 2026

ADCT in upward trend: 10-day moving average crossed above 50-day moving average on September 25, 2026

The 10-day moving average for ADCT crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 23, 2026. You may want to consider a long position or call options on ADCT as a result. In 77 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

ADCT moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +8.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADCT advanced for three days, in 184 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 129 of 151 cases where ADCT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for ADCT moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 53 cases where ADCT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for ADCT turned negative on October 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 46 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

ADCT broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.839) is normal, around the industry mean (11.138). P/E Ratio (-2.586) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.967) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. ADCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

A.I.Advisor
a Summary for SEPN with price predictions
Oct 21, 2026

SEPN in upward trend: price rose above 50-day moving average on October 20, 2026

SEPN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 10 of 10 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SEPN as a result. In 25 of 28 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for SEPN just turned positive on October 20, 2026. Looking at past instances where SEPN's MACD turned positive, the stock continued to rise in 8 of 10 cases over the following month. The odds of a continued upward trend are 80%.

Following a +12.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEPN advanced for three days, in 87 of 98 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for SEPN crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 4 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

SEPN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SEPN entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.920) is normal, around the industry mean (2.988). SEPN has a moderately low P/E Ratio (-76.906) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (17.361) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. SEPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ADCT: Fundamental Ratings
ADCT
OUTLOOK RATING
1..100
29
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
66
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ADCTSEPN
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 2 days ago
89%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 9 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
76%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ADCT: $1.50 vs. SEPN: $40.76)
Brand notoriety: ADCT and SEPN are both not notable
ADCT represents the Pharmaceuticals: Generic, while SEPN is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADCT: 75% vs. SEPN: 63%
Market capitalization -- ADCT: $191.5M vs. SEPN: $1.91B
ADCT [@Pharmaceuticals: Generic] is valued at $191.5M. SEPN’s [@Biotechnology] market capitalization is $1.91B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.33B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADCT’s FA Score shows that 1 FA rating(s) are green while SEPN’s FA Score has 1 green FA rating(s).

  • ADCT’s FA Score: 1 green, 4 red.
  • SEPN’s FA Score: 1 green, 4 red.
According to our system of comparison, ADCT is a better buy in the long-term than SEPN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADCT’s TA Score shows that 5 TA indicator(s) are bullish while SEPN’s TA Score has 4 bullish TA indicator(s).

  • ADCT’s TA Score: 5 bullish, 5 bearish.
  • SEPN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ADCT is a better buy in the short-term than SEPN.

Price Growth

ADCT (@Pharmaceuticals: Generic) experienced а +3.45% price change this week, while SEPN (@Biotechnology) price change was +12.22% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ADCT is expected to report earnings on Nov 09, 2026.

SEPN is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.94% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ADCT
Daily Signal:
Gain/Loss:
SEPN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

SEPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SEPN has been loosely correlated with SRRK. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SEPN jumps, then SRRK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SEPN
1D Price
Change %
SEPN100%
+3.58%
SRRK - SEPN
41%
Loosely correlated
+3.97%
KURA - SEPN
40%
Loosely correlated
-1.00%
RYTM - SEPN
40%
Loosely correlated
-1.75%
TSHA - SEPN
38%
Loosely correlated
+0.24%
STOK - SEPN
37%
Loosely correlated
-3.49%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
COSO27.230.13
+0.48%
CoastalSouth Bancshares Inc
PRMB20.030.03
+0.15%
Primo Brands Corp.
PG156.84-2.48
-1.56%
Procter & Gamble Company
NXB1.67-0.04
-2.34%
Nextboat Inc.
SBH16.60-0.45
-2.64%
Sally Beauty Holdings